The antidepressant actions of ketamine and its enantiomers

JN Johnston, ID Henter, CA Zarate Jr - Pharmacology & therapeutics, 2023‏ - Elsevier
Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …

Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis

ATH Kwan, KM Teopiz, S Wong, JD Rosenblat… - Journal of Affective …, 2024‏ - Elsevier
Background Ketamine has been established as efficacious in adults living with Treatment-
resistant Depression (TRD). Toward providing a quantifiable estimate of the clinical …

Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment …

G Martinotti, B Dell'Osso, G Di Lorenzo… - Bipolar …, 2023‏ - Wiley Online Library
Background Bipolar depression accounts for most of the disease duration in type I and type
II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals …

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data

G d'Andrea, M Pettorruso, G Di Lorenzo… - Journal of Affective …, 2024‏ - Elsevier
Abstract Introduction Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS)
are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies …

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

JJ Breeksema, A Niemeijer, E Krediet, T Karsten… - Scientific Reports, 2024‏ - nature.com
Psilocybin is the most researched classic psychedelic for Treatment-Resistant Depression
(TRD). While optimizing set and setting are considered essential for efficacy and safety …

Rethinking ketamine and esketamine action: are they antidepressants with mood-stabilizing properties?

G d'Andrea, M Pettorruso, G Di Lorenzo… - European …, 2023‏ - Elsevier
Ketamine and esketamine, the S-enantiomer of the racemic mixture, have recently
generated considerable interest as potential therapeutic agents for Treatment-Resistant …

[HTML][HTML] Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)

M Pettorruso, R Guidotti, G d'Andrea, L De Risio… - Psychiatry …, 2023‏ - Elsevier
Abstract Treatment-resistant depression (TRD) represents a severe clinical condition with
high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been …

[HTML][HTML] Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of …

S Chiappini, G d'Andrea, S De Filippis… - European …, 2023‏ - Elsevier
Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-
resistant depression (TRD), showing both rapid antidepressant action and good efficacy and …

[HTML][HTML] The efficacy and safety of intranasal formulations of ketamine and esketamine for the treatment of major depressive disorder: a systematic review

L Boudieu, M Mennetrier, PM Llorca, L Samalin - Pharmaceutics, 2023‏ - mdpi.com
Ketamine and its enantiomers represent an innovative glutamatergic agent as a treatment
for individuals with treatment-resistant depression (TRD) and major depressive disorder …

Personalized use of ketamine and esketamine for treatment-resistant depression

GC Medeiros, I Demo, FS Goes, CA Zarate Jr… - Translational …, 2024‏ - nature.com
A large and disproportionate portion of the burden associated with major depressive
disorder (MDD) is due to treatment-resistant depression (TRD). Intravenous (R, S)-ketamine …